Despite strong headwinds, there may be hope for this biotech.
News & Analysis: Gilead Sciences
Gilead Sciences' revenues are being boosted by its COVID-19 treatment, but it will still be a good investment in a post-pandemic world.
They pay more than double what you'd earn with the average stock in the S&P 500.
With Veklury, Gilead delivered solid revenue growth in Q1. Without the COVID drug, it was an entirely different story.
GILD earnings call for the period ending March 31, 2021.
Gilead Sciences had a stellar 2020, but this year is looking a little more perilous.
Too bad there are issues with side effects.
This is one contrarian investment you don't want to miss out on.
In a post-pandemic world, one company has the lower valuation and higher dividend yield to be a success.
These two big rivals could present a much bigger threat to GlaxoSmithKline and its Viiv Healthcare joint venture.